SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the...
Hence then, the article about dualitybio s next generation her3 adc db 1310 granted fda fast track designation was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation )
Also on site :
- Kenya confirms first Ebola case after patient dies
- Experience ‘Harry Potter and the Half-Blood Prince’ in Stunning New Art; Illustrator Levi Pinfold Details the Process
- This Startup Led by an Ex-Apple Designer Thinks a GUI for AI Could Change Everything